[RECIST classifications : our experience at a university hospital]

Since the WHO [World Health Organization]'s criteria published in 1981, many organizations and research teams worked on revising and defining criteria for response monitoring of solid tumors. The RECIST criteria in 2000 and its revised version in 2009 introduced major changes in selecting lesions to be assessed and measuring them, and determining treatment response. While treatments are becoming more specific with the emergence of targeted therapies, response criteria are becoming more diversified and specialized with a type of tumor or/and treatment. This review describes the evolution of response criteria methods and sketches our experience in this field in Lebanon

Une cause exceptionnelle de myelopathie aigue: La Fistule arterio-veineuse durale a la jonction cranio-rachidienne

Dural arteriovenous fistulas [DAVF] account for 10% to 15% of all intracranial arterio-venous malformations. Since the first case published by Woimant et al. in 1982, many type V DAVF, i.e. with spinal venous drainage, have been reported. Fistulas located at the craniocervical junction [CCJ] however, are exceptional and only 10 cases of CCJ fistulas associated with myelopathy have been described.Case. Report: The authors present a 36-year-old male patient without previous medical history, suffering from acute myelopathy Cervical MRI showed multiple serpiginous flow-voids along the cord surface and cerebral an-giography disclosed a dural fistula of the CCJ fed by the right posterior meningeal and occipital arteries. The venous drainage was directed caudally towards the perimedullary veins. Embolization through the occipital artery, using cyanoacrylate, was performed and resulted in complete cure of the malformation with rapid clinical recovery.Discussion: The authors discuss the pathophysiology and clinical consequences of intracranial DAVF with myelopathy [named V, m+], that are usually identical to those of spinal dural fistulas and related to intramedullary venous hypertension.Early treatment is essential to reverse the patients myelopathy. Embolization, if technically possible, is the preferred treatment and cyanoacrylate remains the best embolic agent. Following glue deposition, systemic high-dose steroids should be administered to prevent edema. In conclusion, this is the first case of DAVF of the foramen magnum causing myelopathy to be detected early and cured by glue embolization alone, with rapid and total clinical recovery